CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 2
Detroit, Michigan, United States and 48 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Detroit, Michigan, United States and 83 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 67 other locations
) and prednisone).The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 75 other locations
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 49 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Ann Arbor, Michigan, United States and 231 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Ann Arbor, Michigan, United States and 216 other locations
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...
Phase 1
Detroit, Michigan, United States and 11 other locations
ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic...
Phase 1, Phase 2
Detroit, Michigan, United States and 38 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...
Phase 1
Detroit, Michigan, United States and 40 other locations
Clinical trials
Research sites
Resources
Legal